487 related articles for article (PubMed ID: 16828937)
21. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.
Zeng M; Xu Q; Pichichero ME
Vaccine; 2007 May; 25(18):3588-94. PubMed ID: 17293013
[TBL] [Abstract][Full Text] [Related]
22. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
[TBL] [Abstract][Full Text] [Related]
23. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
24. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
Gaur R; Gupta PK; Banerjea AC; Singh Y
Vaccine; 2002 Jun; 20(21-22):2836-9. PubMed ID: 12034111
[TBL] [Abstract][Full Text] [Related]
25. A dually active anthrax vaccine that confers protection against both bacilli and toxins.
Rhie GE; Roehrl MH; Mourez M; Collier RJ; Mekalanos JJ; Wang JY
Proc Natl Acad Sci U S A; 2003 Sep; 100(19):10925-30. PubMed ID: 12960361
[TBL] [Abstract][Full Text] [Related]
26. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles.
Sloat BR; Cui Z
Pharm Res; 2006 Feb; 23(2):262-9. PubMed ID: 16319999
[TBL] [Abstract][Full Text] [Related]
27. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice.
Wui SR; Kim HK; Han JE; Kim JM; Kim YH; Chun JH; Cho YJ; Lee NG
Int Immunopharmacol; 2011 Sep; 11(9):1195-204. PubMed ID: 21492746
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of mucoadhesive carrier adjuvant: toward an oral anthrax vaccine.
Mangal S; Pawar D; Agrawal U; Jain AK; Vyas SP
Artif Cells Nanomed Biotechnol; 2014 Feb; 42(1):47-57. PubMed ID: 23452384
[TBL] [Abstract][Full Text] [Related]
29. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
[TBL] [Abstract][Full Text] [Related]
30. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
33. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions.
Cote CK; Rossi CA; Kang AS; Morrow PR; Lee JS; Welkos SL
Microb Pathog; 2005; 38(5-6):209-25. PubMed ID: 15925272
[TBL] [Abstract][Full Text] [Related]
34. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.
Baillie LW; Rodriguez AL; Moore S; Atkins HS; Feng C; Nataro JP; Pasetti MF
Vaccine; 2008 Nov; 26(48):6083-91. PubMed ID: 18805452
[TBL] [Abstract][Full Text] [Related]
35. A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax.
Oscherwitz J; Yu F; Cease KB
J Immunol; 2010 Sep; 185(6):3661-8. PubMed ID: 20696862
[TBL] [Abstract][Full Text] [Related]
36. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
[TBL] [Abstract][Full Text] [Related]
37. Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine.
Schneerson R; Kubler-Kielb J; Liu TY; Dai ZD; Leppla SH; Yergey A; Backlund P; Shiloach J; Majadly F; Robbins JB
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8945-50. PubMed ID: 12857944
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of a subunit vaccine against Bacillus anthracis.
Chichester JA; Musiychuk K; de la Rosa P; Horsey A; Stevenson N; Ugulava N; Rabindran S; Palmer GA; Mett V; Yusibov V
Vaccine; 2007 Apr; 25(16):3111-4. PubMed ID: 17280756
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of immune response to orally administered Sterne strain 34F2 anthrax vaccine.
Shakya KP; Hugh-Jones ME; Elzer PH
Vaccine; 2007 Jul; 25(29):5374-7. PubMed ID: 17555849
[TBL] [Abstract][Full Text] [Related]
40. Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model.
Makam SS; Kingston JJ; Harischandra MS; Batra HV
Mol Immunol; 2014 May; 59(1):91-9. PubMed ID: 24513572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
